We report brigatinib long-term efficacy and safety from phase 1/2 and phase 2 (ALTA) trials in ALK-rearrangement positive (ALK+) NSCLC.

Long-Term Efficacy and Safety of Brigatinib in Crizotinib-Refractory ALK+ NSCLC: Final Results of the Phase 1/2 and Randomized Phase 2 (ALTA) Trials / Gettinger, Scott N; Huber, Rudolf M; Kim, Dong-Wan; Bazhenova, Lyudmila; Hansen, Karin Holmskov; Tiseo, Marcello; Langer, Corey J; Paz-Ares Rodríguez, Luis G; West, Howard L; Reckamp, Karen L; Weiss, Glen J; Smit, Egbert F; Hochmair, Maximilian J; Kim, Sang-We; Ahn, Myung-Ju; Kim, Edward S; Groen, Harry J M; Pye, Joanna; Liu, Yuyin; Zhang, Pingkuan; Vranceanu, Florin; Camidge, D Ross. - In: JTO CLINICAL AND RESEARCH REPORTS. - ISSN 2666-3643. - 3:9(2022), p. 100385. [10.1016/j.jtocrr.2022.100385]

Long-Term Efficacy and Safety of Brigatinib in Crizotinib-Refractory ALK+ NSCLC: Final Results of the Phase 1/2 and Randomized Phase 2 (ALTA) Trials

Tiseo, Marcello;
2022-01-01

Abstract

We report brigatinib long-term efficacy and safety from phase 1/2 and phase 2 (ALTA) trials in ALK-rearrangement positive (ALK+) NSCLC.
2022
Long-Term Efficacy and Safety of Brigatinib in Crizotinib-Refractory ALK+ NSCLC: Final Results of the Phase 1/2 and Randomized Phase 2 (ALTA) Trials / Gettinger, Scott N; Huber, Rudolf M; Kim, Dong-Wan; Bazhenova, Lyudmila; Hansen, Karin Holmskov; Tiseo, Marcello; Langer, Corey J; Paz-Ares Rodríguez, Luis G; West, Howard L; Reckamp, Karen L; Weiss, Glen J; Smit, Egbert F; Hochmair, Maximilian J; Kim, Sang-We; Ahn, Myung-Ju; Kim, Edward S; Groen, Harry J M; Pye, Joanna; Liu, Yuyin; Zhang, Pingkuan; Vranceanu, Florin; Camidge, D Ross. - In: JTO CLINICAL AND RESEARCH REPORTS. - ISSN 2666-3643. - 3:9(2022), p. 100385. [10.1016/j.jtocrr.2022.100385]
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11381/2933366
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 10
  • ???jsp.display-item.citation.isi??? 9
social impact